Bio-Techne (TECH) Other Non-Current Liabilities (2014 - 2026)
Bio-Techne (TECH) posted quarterly Other Non-Current Liabilities of $21.7 million for Q1 2026, up 38.4% year-over-year from $15.7 million in Q1 2025, and down 6.11% quarter-over-quarter from $23.1 million in Q4 2025.
Bio-Techne (TECH) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Bio-Techne's Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $21.7 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 38.4% year-over-year to $21.7 million; the TTM figure through Mar 2026 stood at $21.7 million (up 38.4% YoY), while the FY2025 annual figure was $27.1 million, up 105.84% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $21.7 million, down from $23.1 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $27.1 million in Q2 2025, with the low at $5.0 million in Q2 2022.
- The 5-year median for Other Non-Current Liabilities is $12.8 million (2022), against an average of $15.1 million.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities tumbled 72.68% in 2022, then jumped 118.38% in 2023.
- Bio-Techne's Other Non-Current Liabilities stood at $11.3 million in 2022, then jumped by 53.15% to $17.4 million in 2023, then slumped by 34.7% to $11.3 million in 2024, then jumped by 103.56% to $23.1 million in 2025, then slipped by 6.11% to $21.7 million in 2026.
- Business Quant data shows TECH's Other Non-Current Liabilities at $21.7 million in Q1 2026, $23.1 million in Q4 2025, and $23.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Bio-Techne | 11.33 Bn | 11.12 Bn | 208.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.67 Mn |
| Dec 31, 2025 | 23.08 Mn |
| Sep 30, 2025 | 23.81 Mn |
| Jun 30, 2025 | 27.08 Mn |
| Mar 31, 2025 | 15.66 Mn |
| Dec 31, 2024 | 11.34 Mn |
| Sep 30, 2024 | 19.79 Mn |
| Jun 30, 2024 | 13.16 Mn |
| Mar 31, 2024 | 11.56 Mn |
| Dec 31, 2023 | 17.36 Mn |
| Sep 30, 2023 | 9.39 Mn |
| Jun 30, 2023 | 10.92 Mn |
| Mar 31, 2023 | 10.97 Mn |
| Dec 31, 2022 | 11.34 Mn |
| Sep 30, 2022 | 11.50 Mn |
| Jun 30, 2022 | 5.00 Mn |
| Mar 31, 2022 | 12.77 Mn |
| Dec 31, 2021 | 7.00 Mn |
| Sep 30, 2021 | 17.60 Mn |
| Jun 30, 2021 | 18.30 Mn |